산후 우울증 치료 시장 : 치료법별, 환자 중증도별, 연령층별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Postpartum Depression Treatment Market is projected to grow by USD 1.80 billion at a CAGR of 7.65% by 2032.

Postpartum depression treatment is moving from episodic, stigma-constrained care toward a systematic maternal mental health model that combines screening, psychotherapy, pharmacotherapy, care navigation, and digital follow-up. The World Health Organization recognizes perinatal mental health conditions as a major public health concern, and the U.S. CDC reports that approximately 1 in 8 women with a recent live birth experience symptoms of postpartum depression, underscoring the need for scalable and timely treatment pathways.

The treatment landscape includes evidence-based psychotherapies such as cognitive behavioral therapy and interpersonal therapy, commonly used antidepressants, and newer neuroactive steroid therapies designed specifically for postpartum depression. Demand is also being shaped by expanded maternal health policies, telebehavioral health adoption, and greater recognition that untreated postpartum depression can affect maternal functioning, infant bonding, breastfeeding, family stability, and long-term child development.

Transformative Shifts in the Treatment Landscape

The most important shift in postpartum depression treatment is the transition from general depression management to condition-specific care. The U.S. FDA approval of brexanolone in 2019 and zuranolone in 2023 validated a dedicated pharmacological pathway for postpartum depression and increased attention on faster-acting options for patients with clinically significant symptoms.

Health systems are also embedding depression screening into obstetric, pediatric, and primary care visits using validated tools such as the Edinburgh Postnatal Depression Scale and PHQ-9. This is changing treatment demand from one-time medication use toward integrated care models that include diagnosis, referral, therapy access, medication management, lactation-aware counseling, and relapse monitoring during the first year after delivery.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant to postpartum depression treatment through risk stratification, symptom monitoring, patient engagement, and clinical workflow support. AI-enabled tools can help identify patients at higher risk by analyzing structured health records, screening scores, prior psychiatric history, obstetric complications, sleep patterns, and social determinants of health, provided models are validated and deployed with clinician oversight.

The cumulative opportunity is not to replace mental health professionals but to reduce delays in detection and follow-up. AI chat interfaces, remote monitoring, and natural language processing can improve outreach between appointments, but industry leaders must address bias, privacy, informed consent, maternal safety, and escalation protocols for suicidality or psychosis. Verified clinical performance, transparent model governance, and regulatory-grade evidence will be critical differentiators.

Key Regional Insights

North America remains a leading region for postpartum depression treatment adoption due to established screening recommendations, U.S. FDA-approved therapies, commercial insurance coverage, Medicaid maternal health initiatives, and high telehealth penetration. The United States has accelerated innovation through dedicated drug approvals and postpartum coverage reforms, while Canada's universal healthcare framework supports broader access to perinatal mental health services, although specialist wait times and rural access gaps remain challenges.

Europe benefits from national health systems, clinical guidance, and growing investment in perinatal mental health teams, particularly in Western Europe. The European Union's focus on women's health equity, cross-border health data standards, and digital health interoperability is strengthening structured care pathways, while country-level reimbursement, workforce availability, and access to specialist perinatal psychiatry continue to influence uptake.

Asia-Pacific presents a substantial long-term access opportunity because of its birth volume, expanding healthcare infrastructure, and rising public awareness in China, India, Japan, South Korea, and Australia. Latin America is gaining momentum through maternal health programs, primary care expansion, and digital consultation models, but affordability, uneven insurance coverage, and specialist shortages limit consistent treatment access. The Middle East, led by GCC health transformation programs, is improving women's health services and digital care delivery, while Africa faces the most significant treatment gap due to workforce shortages, stigma, limited screening, and insufficient integration of mental health into maternal care.

Key Group Insights

Within ASEAN, postpartum depression treatment demand is shaped by rapid urbanization, mobile-first healthcare behavior, and uneven mental health capacity across member states. Digital screening, nurse-led counseling, and community-based maternal care can improve access, but language localization, stigma reduction, referral capacity, and workforce training are essential for sustainable implementation.

The GCC is advancing maternal health through hospital modernization, women's health initiatives, insurance reforms, and national digital health strategies, creating opportunities for premium clinical programs and culturally adapted telepsychiatry. The European Union is positioned for protocol-driven expansion because of strong public health governance, standardized clinical quality expectations, and women's health policy momentum, although reimbursement, prescribing pathways, and service implementation remain country-specific.

BRICS countries represent a high-volume access opportunity because China, India, Brazil, Russia, and South Africa combine large birth populations with expanding healthcare investment and variable access to psychiatric care. G7 markets lead in regulatory sophistication, clinical research, guideline adoption, pharmacovigilance, and reimbursement experimentation. NATO countries add a distinct focus on military families, where deployment stress, relocation, social isolation, and access continuity can intensify maternal mental health needs and require coordinated postpartum depression treatment pathways.

Key Country Insights

The United States is the most commercially mature postpartum depression treatment environment, supported by CDC surveillance, ACOG screening guidance, U.S. FDA-approved therapies, telehealth adoption, and expanding postpartum Medicaid coverage in many states. Canada emphasizes publicly funded care and perinatal mental health programs, while Mexico and Brazil show growing need for scalable screening, telehealth, primary care integration, and lower-cost treatment options to address access gaps.

In Europe, the United Kingdom benefits from NICE guidance and specialist perinatal mental health services within the NHS. Germany and France have strong healthcare systems, reimbursement infrastructure, and growing attention to maternal mental health, Italy and Spain show rising awareness within maternity and primary care pathways, and Russia presents demand potential but faces regional disparities in mental health access and service availability.

Across Asia-Pacific, China and India represent major volume opportunities due to large birth cohorts, improving maternal health systems, and expanding digital healthcare use. Japan, South Korea, and Australia have more developed clinical infrastructure, with Australia standing out for strong public discussion of perinatal mental health and widely available digital support resources. These markets will reward organizations that combine evidence-based treatment, culturally appropriate engagement, lactation-aware counseling, and postpartum follow-up continuity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated care models that connect obstetrics, pediatrics, psychiatry, primary care, pharmacy services, and digital follow-up. Winning strategies will focus on earlier screening, faster referral, evidence-based psychotherapy access, medication safety counseling, lactation-sensitive treatment decisions, and clear escalation pathways for severe depression, suicidality, or postpartum psychosis.

Pharmaceutical, digital health, and provider organizations should build real-world evidence programs to demonstrate symptom improvement, adherence, maternal functioning, patient-reported outcomes, safety, and health economic value. Partnerships with payers, hospitals, community health workers, lactation consultants, and maternal advocacy organizations can improve trust and reduce dropout. Companies should also invest in culturally adapted education, multilingual support, and privacy-first digital engagement to address stigma, underdiagnosis, and care discontinuity.

Research Methodology

This executive summary is based on verified secondary research and triangulated insights from public health agencies, regulatory bodies, clinical guidelines, peer-reviewed literature, and recognized healthcare organizations. Sources considered include the WHO, CDC, U.S. FDA, ACOG, NICE, national health ministries, and published studies on postpartum depression prevalence, screening, clinical burden, and treatment pathways.

The methodology emphasizes data validity over speculative market claims. Findings were assessed by comparing epidemiology, regulatory milestones, treatment pathways, reimbursement signals, digital health adoption, and regional healthcare capacity. Qualitative insights were structured to support focused executive decision-making while avoiding unsupported market sizing, market share, or forecast-based claims.

Conclusion

Postpartum depression treatment is entering a more specialized, evidence-driven phase shaped by condition-specific medicines, broader screening, telehealth, AI-enabled workflow support, and integrated maternal mental healthcare. The opportunity for improved outcomes is significant because postpartum depression is common, underdiagnosed, and associated with measurable health and social consequences when left untreated.

Future leadership will depend on improving access, affordability, clinical validation, safety monitoring, and continuity of care across the postpartum year. Organizations that combine proven therapies with digital enablement, culturally competent outreach, and rigorous evidence standards will be best positioned to improve outcomes for mothers, infants, and families worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Postpartum Depression Treatment Market, by Treatment Type

• 7.1. Non-Pharmacological
  • 7.1.1. Psychotherapy
    • 7.1.1.1. Cognitive Behavioral Therapy
    • 7.1.1.2. Interpersonal Therapy
  • 7.1.2. Neuromodulation
  • 7.1.3. Digital Therapeutics
    • 7.1.3.1. Mobile App-based Therapy
    • 7.1.3.2. Telehealth Counseling
• 7.2. Pharmacological
  • 7.2.1. Antidepressants
    • 7.2.1.1. SSRIs
    • 7.2.1.2. SNRIs
  • 7.2.2. Hormonal Therapy
  • 7.2.3. Neuroactive Steroid Therapy
    • 7.2.3.1. Brexanolone-based
    • 7.2.3.2. Zuranolone-based

8. Postpartum Depression Treatment Market, by Patient Severity

• 8.1. Mild
• 8.2. Moderate
• 8.3. Severe

9. Postpartum Depression Treatment Market, by Age Group

• 9.1. Below 25 Years
• 9.2. Between 25 To 44 Years
• 9.3. Above 44 Years

10. Postpartum Depression Treatment Market, by End User

• 10.1. Hospitals
• 10.2. Specialty Clinics
• 10.3. Mental Health Centers
• 10.4. Homecare Settings

11. Postpartum Depression Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Postpartum Depression Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Postpartum Depression Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Postpartum Depression Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc
• 16.2. Acadia Pharmaceuticals Inc
• 16.3. Amneal Pharmaceuticals LLC
• 16.4. AstraZeneca plc
• 16.5. Aurobindo Pharma Ltd
• 16.6. Axsome Therapeutics Inc
• 16.7. Biogen Inc
• 16.8. Brii Biosciences Limited
• 16.9. Dr Reddys Laboratories Ltd
• 16.10. Eli Lilly and Company
• 16.11. GH Research Ireland Limited
• 16.12. H. Lundbeck AS
• 16.13. Johnson & Johnson Services, Inc.
• 16.14. Lupin Ltd
• 16.15. Marinus Pharmaceuticals Inc
• 16.16. Merck & Co Inc
• 16.17. Mitsubishi Tanabe Pharma Corporation
• 16.18. Novartis AG
• 16.19. Otsuka Pharmaceutical Co Ltd
• 16.20. Pfizer Inc
• 16.21. Sage Therapeutics Inc
• 16.22. Sanofi SA
• 16.23. Takeda Pharmaceutical Company Limited
• 16.24. Teva Pharmaceutical Industries Ltd